Here's Why Exact Sciences (EXAS) is a Strong Growth Stock

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score emphasizes identifying undervalued stocks using financial ratios [3] - Growth Score focuses on a company's financial health and future growth potential [4] - Momentum Score identifies trends in stock prices and earnings estimates to optimize entry points [5] - VGM Score combines all three styles to highlight stocks with the best overall characteristics [6] Zacks Rank and Style Scores Interaction - The Zacks Rank utilizes earnings estimate revisions to guide investors in stock selection, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.75% since 1988 [7] - The combination of Zacks Rank and Style Scores helps investors narrow down their choices among numerous top-rated stocks [8] - Stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B are recommended for maximizing returns [9] Company Spotlight: Exact Sciences (EXAS) - Exact Sciences Corporation specializes in molecular diagnostics for early cancer detection, focusing on colorectal cancer screening, molecular residual disease testing, and multi-cancer screening [11] - EXAS holds a Zacks Rank of 3 (Hold) and has a VGM Score of A, indicating solid potential [11] - The company is projected to experience significant growth, with a year-over-year earnings growth forecast of 226.1% for the current fiscal year [12] - Recent analyst revisions have positively impacted earnings estimates, with an increase from $0.24 to $0.29 per share [12] - EXAS has demonstrated an impressive average earnings surprise of +329.9%, making it a strong candidate for growth investors [12][13]